

CERTIFICATE OF ANALYSIS

Melanotan I - 10 mg


Synthetic alpha-MSH analogue - reference-standard identity - lyophilised

Material	Melanotan I	Client	novumpeptides.com	Received	2026-05-18 at 2-8 C
Batch / lot	PEP-15-6RP	Label claim	10 mg	Analysed	2026-05-19 to 2026-05-20

TEST RESULTS

ATTRIBUTE	RESULT	SPECIFICATION	METHOD	VERDICT
Identity	Conforms	Matches reference	MA-MS-014 / LC-HRMS	Conforms
Purity (area %)	99.48%	$\geq 99.00\%$	MA-UHPLC-031 / UV 214	Pass
Largest single impurity	0.15%	$\leq 0.50\%$	MA-UHPLC-031 / UV 214	Pass
Total related substances	0.52%	$\leq 1.00\%$	MA-UHPLC-031 / UV 214	Pass
Melanotan I per vial	10.02 mg	9.00-11.00 mg	MA-ASSAY-011 / UHPLC-UV	Pass
Water content	4.04%	$\leq 8.00\%$	MA-KF-004 / Karl Fischer	Pass
Residual acetonitrile	171 ppm	≤ 410 ppm	MA-GC-006 / HS-GC-FID	Pass
Residual TFA	0.16%	$\leq 1.00\%$	MA-IC-003 / ion chromatography	Pass

RP-UHPLC processed trace, UV detection



Record KGCY6RP-PEP-01; duplicate independent preparations. System suitability met retention-time and resolution criteria; blank response was below threshold.

Related species > 0.05%

deletion sequence	0.15%
insertion sequence	0.11%
diastereomeric variant	0.08%
N-terminal variant	0.06%
C-terminal variant	0.05%
unresolved peaks	0.07%

Related species were assigned by orthogonal reference comparison and mass-spectrometric or chromatographic evidence. Mean area percentages; reporting threshold 0.05%.

Conclusion

Identity and quality attributes met the stated criteria. Mean Melanotan I content was 10.02 mg/vial and chromatographic purity was 99.48%.

Identity was established by LC-HRMS against a qualified reference; content and related substances were assessed independently.

Analytical review

Ines Abadi *I. Abadi*

Quality review

Marcus Oyelaran

Approval date: 2026-05-21 *M. Oyelaran*

Decision rule: guarded acceptance; reported outcomes account for method uncertainty and remain within the stated project specifications.